Proleukin

Phase 2Protein / enzyme

IImCheck Therapeutics

Proleukin is one of 84 small molecule programs targeting Alzheimer disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseActive, not recruiting

Metastatic MelanomaRecruiting

Alzheimer DiseasePhase 2

Active, not recruiting

Metastatic MelanomaPhase 1

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Eisai

Approved

1 2

Avandia

Estrace

Aleve

Epidiolex

Rifadin

Cialis

Farxiga

Victoza

Avelox

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Metastatic Melanoma

NCT06204991

Phase 2Active, not recruiting

Alzheimer Disease

NCT05468073

Clinical

Trials by Indication[1]

Childhood Acute Myeloid Leukemia1 trial

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00149162·580 enrolled

Autoimmune Encephalitis1 trial

IL-2 in Refractory Autoimmune Encephalitis

Completed·SSeoul National University Hospital·Phase 1/2·NCT02714959·10 enrolled

Metastatic Melanoma1 trial

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

Recruiting·IInge Marie Svane·Phase 1·NCT06204991·10 enrolled

Vasculitis1 trial

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 1/2·NCT00574652·10 enrolled

Nephrotic Syndrome1 trial

IL-2 for Multi Drug Resistant Nephrotic Syndrome

Completed·IIstituto Giannina Gaslini·Phase 1/2·NCT02455908·5 enrolled

6 more indications

Cell Therapy1 trial

Adoptive Cell Therapy Across Cancer Diagnoses

Completed·IInge Marie Svane·Phase 1/2·NCT03296137·25 enrolled

Urothelial Carcinoma1 trial

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Unknown status·SSheba Medical Center·Phase 2·NCT04383067·20 enrolled

Interleukin1 trial

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Completed·UUniversity of Minnesota·Phase 3·NCT00013611·1,695 enrolled

Acute Coronary Syndrome1 trial

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Completed·—·Phase 1/2·NCT03113773·41 enrolled

Solid Tumor, Adult1 trial

A Two-part, Open-label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 in Combination With Low-dose Subcutaneous Interleukin-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Terminated·IImCheck Therapeutics·Preclinical·NCT05307874·56 enrolled

Alzheimer disease1 trial

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Active, not recruiting·CCentre Hospitalier St Anne·Phase 2·NCT05468073·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Proleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImCheck Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: IImCheck Therapeutics

Proleukin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Childhood Acute Myeloid Leukemia1 trial

Autoimmune Encephalitis1 trial

Metastatic Melanoma1 trial

Vasculitis1 trial

Nephrotic Syndrome1 trial

Cell Therapy1 trial

Urothelial Carcinoma1 trial

Interleukin1 trial

Acute Coronary Syndrome1 trial

Solid Tumor, Adult1 trial

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News